尹艷飛
[摘要] 目的 探究六味地黃丸聯(lián)合消渴丸治療2型糖尿病臨床效果。 方法 將2018年1—12月該院治療的2型糖尿病患者86例納入研究,將之分為兩組,每組43例,對照組給予消渴丸治療,觀察組給予六味地黃丸聯(lián)合消渴丸進(jìn)行醫(yī)治,醫(yī)治結(jié)束后比較兩組醫(yī)治療效。 結(jié)果 經(jīng)積極醫(yī)治后,兩組的FPG、2 hPG、HbAlc指標(biāo)水平均降低,但觀察組降低程度大于對照組,在治療總有效率上,觀察組為95.35%,高于對照組的76.74%,兩組數(shù)據(jù)差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 六味地黃丸聯(lián)合消渴丸治療2型糖尿病,降糖效果顯著,值得采納應(yīng)用。
[關(guān)鍵詞] 六味地黃丸;消渴丸;2型糖尿病;臨床效果
[中圖分類號] R28? ? ? ? ? [文獻(xiàn)標(biāo)識碼] A? ? ? ? ? [文章編號] 1672-4062(2019)08(b)-0075-02
[Abstract] Objective To investigate the clinical effect of Liuwei Dihuang Pill combined with Xiaoke Pill in the treatment of type 2 diabetes mellitus. Methods 86 patients with type 2 diabetes mellitus treated in our hospital from January to December 2018 were enrolled in the study. They were divided into two groups, 43 cases in each group. The control group was given Xiaoke Pills. The observation group was given Liuwei Dihuang Pills. The joint Xiaoke Pills was used for treatment, and the therapeutic effects of the two groups were compared after the treatment. Results After active treatment, the levels of FPG, 2 hPG and HbAlc in the two groups decreased, but the decrease in the observation group was greater than that in the control group. In the total effective rate of treatment, the observation group was 95.35%, which was higher than the control group of 76.74%, and the data were significantly different (P<0.05), which was statistically significant. Conclusion Liuwei Dihuang Pill combined with Xiaoke Pill in the treatment of type 2 diabetes has significant hypoglycemic effect and is worthy of adoption.
[Key words] Liuwei Dihuang Pill; Xiaoke Pill; Type 2 diabetes; Clinical effect
顯差異;ER、RR、HER2、Ki-67表達(dá)情況可為乳腺癌預(yù)后的判斷、臨床治療方案的制定提供幫助,但兩組數(shù)據(jù)對比差異不大;觀察組患者的5年生存率更低,說明合并2型糖尿病的乳腺癌患者的預(yù)后效果更差,分析原因在于,糖尿病在合并2型糖尿病的乳腺癌患者治療中會對臨床療效產(chǎn)生不良影響,因此導(dǎo)致預(yù)后效果不如單純?nèi)橄侔┗颊?,另外糖尿病患者存在高胰島素血癥,會增加IGF合成量及活性[5],參與了腫瘤的浸潤、轉(zhuǎn)移過程[6-7],因此合并2型糖尿病的乳腺癌患者存在較高的復(fù)發(fā)轉(zhuǎn)移率,提示糖尿病是影響乳腺癌患者療效和預(yù)后的重要因素。
綜上所述,合并2型糖尿病的乳腺癌患者具有更高的組織學(xué)分級,發(fā)生三陰性乳腺癌的風(fēng)險(xiǎn)更高,且預(yù)后效果不如乳腺癌患者。
[參考文獻(xiàn)]
[1]? 何唐艷.合并2型糖尿病的激素依賴型乳腺癌患者的臨床特點(diǎn)及預(yù)后[D].廣西:廣西醫(yī)科大學(xué),2017.
[2]? 田曉菲,李碧麗.合并2型糖尿病乳腺癌患者的臨床病理特征分析[J].現(xiàn)代醫(yī)學(xué),2017,45(2):239-243.
[3]? 王海燕,權(quán)毅.合并2型糖尿病的乳腺癌的臨床病理特征及預(yù)后研究[J].瀘州醫(yī)學(xué)院學(xué)報(bào),2016,39(5):446-450.
[4]? 曹敏.乳腺癌合并2型糖尿病患者的臨床特征及預(yù)后[J].中國衛(wèi)生標(biāo)準(zhǔn)管理,2016,7(22):15-17.
[5]? 康世瑾,安淑敏,劉志遠(yuǎn),等.合并2型糖尿病的乳腺癌的臨床病理特征及預(yù)后研究[J].糖尿病新世界,2016,19(6):59-60.
[6]? 劉桂紅,周衛(wèi)華,張玉娜,等.乳腺癌合并2型糖尿病患者的臨床病理特征及預(yù)后分析[J].河北醫(yī)科大學(xué)學(xué)報(bào),2016,37(3):249-251,255.
[7]? 李麗慧,高宇,陳海蘭,等.乳腺癌合并2型糖尿病患者臨床病理特征分析[J].承德醫(yī)學(xué)院學(xué)報(bào),2015,32(2):126-128.
(收稿日期:2019-05-21)